Talk:Tirzepatide

Medicine: Gastroenterology Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.
	This article is supported by the Gastroenterology task force (assessed as Low-importance).

Pharmacology High‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
High	This article has been rated as High-importance on the project's importance scale.

Chemicals Low‑importance

	This article is within the scope of WikiProject Chemicals, a daughter project of WikiProject Chemistry, which aims to improve Wikipedia's coverage of chemicals. To participate, help improve this article or visit the project page for details on the project.ChemicalsWikipedia:WikiProject ChemicalsTemplate:WikiProject Chemicalschemicals articles
Low	This article has been rated as Low-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Tirzepatide.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Adverse effects

I noticed that an IP editor removed a near-duplicate sentence from the lead which Whywhenwhohow added back today. I would agree with the IP editor that the WP:lead, which should merely be summarising the important aspects of the main article, doesn't need such a strong focus on adverse effects. Perhaps Whywhenwhohow would like to explain their justification for this? Mike Turnbull (talk) 13:06, 5 January 2023 (UTC)[reply]

It has been a practice in articles about medications to include the common side effects in the lead. --Whywhenwhohow (talk) 22:03, 5 January 2023 (UTC)[reply]

@Whywhenwhohow You are missing the point. The lead currently says Common side effects may include nausea, vomiting, diarrhea, constipation, upper abdominal discomfort, and abdominal pain. [paragraph break] The most common side effects include nausea, vomiting, diarrhea, decreased appetite, constipation, upper abdominal discomfort and abdominal pain. Why do we need the repetition? Surely the single sentence Common side effects may include nausea, vomiting, diarrhea, constipation, upper abdominal discomfort, and abdominal pain. would suffice, which is what was there after the IP editor removed the additional paragraph. Mike Turnbull (talk) 10:51, 6 January 2023 (UTC)[reply]

Sorry about that. I was missing the point and fixed it. --Whywhenwhohow (talk) 23:48, 6 January 2023 (UTC)[reply]

Comparison with Semaglutide and Dulaglutide

A family memory was briefly put on Semaglutide but had bad reactions. Looking for the topic in google, without knowing the name for the drug, led me to this page instead.

This article seems to describe a drug that works exactly like Semaglutide, in that they are both (primarily) injectable GLP-1 antagonists that increase insulin secretion, and as a side-effect have appetite suppression qualities. It seems the same is true for Dulaglutide as well.

While there are a number of similar drugs found in the GLP category, I think that as, as far as I can tell, the three most popular members of the family, there should be some direct comparison in each of these articles. What makes Tirzepatide different than Semaglutide? I suspect that is why most people would come to this article in the first place. 108.168.93.43 (talk) 15:01, 5 January 2023 (UTC)[reply]

IP editor: It isn't Wikipedia's role to give medical advice or to compare treatments, except perhaps to quote what external publications such as the current reference #23 states. Wikipedia editors are not required to be experts in the topics they write about, we just summarise reliable sources. Mike Turnbull (talk) 15:11, 5 January 2023 (UTC)[reply]

Surely there is some information out there someone could summarize to answer this question? 108.168.93.43 (talk) 23:23, 7 January 2023 (UTC)[reply]

Probably not yet. Tirzepatide only entered the clinic in May to November 2022 in various countries so it will take some time before meaningful comparative studies are published. Once they are, then of course they can be summarized here. Mike Turnbull (talk) 13:11, 8 January 2023 (UTC)[reply]

Comparison with ketogenic diets

Adding a section comparing this and similar medications with ketogenic diets would be helpful to readers. These diets shift human metabolism from glycolysis to ketosis, providing control for type 2 diabetes, weight normalization, and circulatory benefits, as shown by published clinical studies. In addition, ketogenic diets lack the many possible unwanted side effects of the medications. David Spector (talk) 12:06, 12 January 2024 (UTC)[reply]

As commented in the section above, it is not Wikipedia's role to make such comparisons unless we can quote WP:MEDRS-compliant sources which have done so. Anything else would be original research. Can you suggest here the sources you would propose to use? Mike Turnbull (talk) 16:33, 12 January 2024 (UTC)[reply]

Up to date nomenclature

Shouldn't all instances of things like "weight loss" and "for weight loss" be changed to "obesity" and "for the treatment of obesity"? — Preceding unsigned comment added by 2607:FEA8:125D:F800:2008:D73E:880:5598 (talk) 11:37, 29 June 2024 (UTC)[reply]

Obesity is a defined medical condition usually for people with a BMI > 30. Tirzepatide and other similar medications like semaglutide are, somewhat notoriously, being used for weight loss in people who would not be defined as obese. The correct thing to do, IMO, would be to use the term most commonly used in our cited sources but I haven't checked what these are. Mike Turnbull (talk) 12:50, 30 June 2024 (UTC)[reply]

Brand names section

The brand names section is superfluous and any info from it should be merged with that of the introduction section. Machinelemonade (talk) 22:59, 15 August 2024 (UTC)[reply]

Why two brands

The article should explain why the same substance administered in the same way is marketed under different brand names for each indication. 2603:400A:0:7EC:0:0:801E:1C14 (talk) 20:40, 16 October 2024 (UTC)[reply]